Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression).
$42.01+10.29%
报价 2026-11-06
市值
$1.36B
EV
$956.6M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -15.1%
$14.61$49.48
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LBRXLB Pharmaceuticals Inc Common Stock | $1.36B | +10.3% | – | 0% | – | – | – | |
| SLDBSolid Biosciences Inc. | $706.6M | +6.6% | +146.7% | 0% | – | – | – | |
| ANNXAnnexon, Inc. | $688.1M | +4.9% | -77.8% | 0% | – | – | – | |
| AURAAura Biosciences, Inc. | $680.3M | +3.5% | +2.7% | 0% | – | – | – | |
| DSGNDesign Therapeutics, Inc. | $639M | +5.6% | +141.9% | 0% | – | – | – | |
| ALTAltimmune, Inc. | $404.6M | +5.6% | -100.0% | -36,387.8% | – | – | – | |
| AUTLAutolus Therapeutics plc | $340.7M | +1.6% | – | 15.7% | – | – | – | |
| RCKTRocket Pharmaceuticals, Inc. | $261.8M | -2.1% | +360.0% | 0% | – | – | – | |
| DBVTDBV Technologies S.A. | $250M | +6.6% | – | -110.7% | – | – | – | |
| 同行中位数 | – | – | +72.3% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。